SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.
Angelini Pharma, a subsidiary of conglomerate Angelini, agreed yesterday to buy Arvelle Therapeutics, a central nervous system (CNS) disorder drug developer spun off by pharmaceutical company Axovant, for up to $960m. The deal will involve a $610m upfront payment, with up to $350m in additional capital to be paid should Arvelle’s epilepsy drug, cenobamate, achieve…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.